Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1017/cjn.2022.36 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neutrophilic Panniculitis Secondary to BRAF and MEK Inhibitor Therapy to Treat Stage IIIa Cutaneous Melanoma.
J Cutan Pathol
January 2025
Department of Dermatology, San Antonio Uniformed Services Health Consortium (SAUSHEC), San Antonio, Texas, USA.
Panniculitides are a group of inflammatory disorders of the subcutaneous fat that have been reported as a rare complication of both a serine threonine kinase BRAF inhibitor monotherapy and BRAF inhibition in combination with a mitogen activated protein kinase (MEK) inhibitor combination therapy used to treat metastatic melanoma. The cutaneous manifestations of BRAF and BRAF/MEK therapies have been well documented, but neutrophilic panniculitis remains a less common complication with fewer case reports. Physician awareness of this complication when following patients on similar targeted therapies can decrease delays in appropriate management.
View Article and Find Full Text PDF[Not Available].
Bull Cancer
October 2024
Département d'imagerie, Service d'oncologie endocrinienne, Gustave-Roussy, Villejuif, F-94805, France. Electronic address:
LATEST DEVELOPMENTS IN ANAPLASTIC THYROID CARCINOMA MANAGEMENT IN 2024: Anaplastic thyroid carcinomas (ATCs) represent a rare and undifferentiated form of thyroid cancer with a poor prognosis, typically marked by a median overall survival of four to ten months. However, recent advances have shown improvements due to the more systematic application of molecular testing, targeted therapies, and immunotherapy, alongside the establishment of rapid specialized care protocols in expert centers. Clinically, ATCs often present as a rapidly enlarging cervical mass originating from the thyroid, causing neck, pain and tenderness, dyspnea and dys-phagia, and associated lymphadenopathy, typically in elderly patients.
View Article and Find Full Text PDFA novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery.
PLoS One
November 2024
Thurston Arthritis Research Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Osteoarthritis (OA) is the most common form of arthritis and a leading cause of pain and disability in adults. A central feature is progressive cartilage degradation and matrix fragment formation driven by the excessive production of matrix metalloproteinases (MMPs), such as MMP-13, by articular chondrocytes. Inflammatory factors, including interleukin 6 (IL-6), are secreted into the joint by synovial fibroblasts, and can contribute to pain and inflammation.
View Article and Find Full Text PDFCobb syndrome effectively treated with trametinib.
Ann Clin Transl Neurol
October 2024
Department of Interventional Therapy, Multidisciplinary Team of Vascular Anomalies, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, No. 639, Zhizaoju Road, Shanghai, PR China.
Cobb syndrome is a rare neurocutaneous disease characterized by vascular anomalies involving the skin and spinal cord at the same metamere. The most common initial symptoms are neurological manifestations such as pain, monoparesis, headache, scoliosis, and motor damage. We present two patients with Cobb syndrome and severe disease burden harboring somatic mutations in KRAS.
View Article and Find Full Text PDFIs It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials?
Clin Cancer Res
October 2024
Division of Medical Oncology, Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, Missouri.
Article Synopsis
- - Epithelioid hemangioendothelioma is a very rare type of cancer that is caused by a fusion of the YAP and CAMTA1 genes.
- - A phase 2 clinical trial known as SARC33 tested trametinib, a drug related to the MEK signaling pathway, but the trial did not meet its main goals based on RECIST criteria.
- - However, the trial showed positive patient-reported outcomes, indicating that participants experienced less pain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!